A diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) often emerges during a routine medical examination or imaging study. Doctors frequently detect the condition when blood tests show raised liver enzymes or imaging reveals fat accumulation in the liver. Key risk factors—such as obesity, type 2 diabetes, hypertension, or abnormal cholesterol levels—increase the chances of progression from metabolic dysfunction-associated steatotic liver disease (MASLD) to its more severe form, MASH. Unlike MASLD, MASH features inflammation and potential scarring (fibrosis) in the liver, though early-stage damage may still be reversible with timely treatment.
Biopsy Decisions: When Is It Necessary?
A liver biopsy remains the definitive method for confirming MASH, though it is not always required. Clinicians may recommend one if imaging or blood tests indicate advanced fibrosis or if a patient’s symptoms do not match other findings. In most cases, non-invasive tests like elastography, which measures liver stiffness, can track disease progression without the risks of a biopsy. The decision hinges on whether a patient has known fibrosis, metabolic comorbidities, or unexplained spikes in liver enzymes.
The condition can progress silently over years, with up to one in five patients advancing to cirrhosis, a late-stage scarring that heightens the risk of liver cancer. Untreated fibrosis becomes increasingly difficult to reverse over time.
Treatment Options: Weight Loss and Medications
Weight loss represents the most effective strategy for improving MASH and early fibrosis. Research demonstrates that losing more than 10% of body weight can significantly reduce liver fat and inflammation. For patients struggling with obesity or diabetes, GLP-1 medications like semaglutide (Wegovy) are now FDA-approved specifically for MASH treatment. These drugs help regulate blood sugar, suppress appetite, and promote weight loss, critical factors in slowing liver damage.
When GLP-1 therapies prove unsuitable, due to side effects, cost, or insufficient response, resmetirom (Rezdiffra) provides an alternative. This medication targets liver fat directly and has demonstrated potential in reversing fibrosis, although long-term data on its use remain limited. Both treatments demand sustained commitment: GLP-1 drugs are typically required for life, while resmetirom’s duration depends on individual response and insurance approval.
You should limit drinks to less than 14 drinks per week or less than 4 drinks per day for males and less than 7 drinks per week or less than 3 drinks per day for females.
Diagnostic Confirmation and Risk Assessment for MASH Progression
MASH is considered serious due to its potential to advance to cirrhosis, which affects up to one in five patients with the condition. The progression from early fibrosis to cirrhosis typically takes 10 to 20 years, though the timeline can vary.
Tracking Progress and Adjusting Care
Lifestyle modifications remain the foundation of MASH management. A 5% to 7% weight loss through diet and exercise can delay or reverse early damage, often without medication. For individuals with metabolic conditions like diabetes, combining lifestyle changes with GLP-1 therapy yields the best results. The choice between medications depends on tolerance, cost, and whether a patient has additional obesity-related health issues.
